Latest News and Press Releases

CF-MEV-132 drug candidate belongs to the CF-MEV family of anti-inflammatory EV drugs produced by The Cell Factory Amsterdam, The Netherlands – 27 February 2019 The Cell Factory and the...

Amsterdam, The Netherlands – 26 February 2019 Esperite N.V. (Euronext: ESP, “Esperite”) announces today a EUR 280,000 private placement of 28 convertible notes with a principal amount of EUR 10,000...

Amsterdam, the Netherlands – 22 February 2019 Esperite N.V. (Euronext: ESP) and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM) are pleased to announce that they have entered into an...

    Amsterdam, The Netherlands - 10 January 2019 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 24th   Tranche of EUR 230,000 is issued as a private placement of 23...

Cette proposition, crédible et créatrice de valeur, vise à donner un nouvel espoir à la société Hybrigenics et ses actionnaires et constitue une alternative à la dissolution anticipée. Amsterdam,...

Amsterdam, The Netherlands - 30 November 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 23rd   Tranche of EUR 220,000 is issued as a private placement of 22...

This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn's, Bronchopulmonary dysplasia, Epilepsy and Stroke ...

Amsterdam, the Netherlands - 27 November 2018 Esperite N.V. (Euronext: ESP, "Esperite") announces that it has convened its Annual General Meeting of Shareholders ("AGM") to be held on 8 January...

    Amsterdam, The Netherlands - 23 November 2018 ESPERITE N.V. (Euronext: ESP, "Esperite", "the Company" or "the Group") has published today its Annual Report for the year ended 31 December 2017....

Amsterdam, The Netherlands - 19 November 2018 Esperite announces that the preparation of its Annual Report 2017 is now under final review by its auditors and should be published before 24...